[go: up one dir, main page]

PE20030925A1 - Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico - Google Patents

Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico

Info

Publication number
PE20030925A1
PE20030925A1 PE2003000056A PE2003000056A PE20030925A1 PE 20030925 A1 PE20030925 A1 PE 20030925A1 PE 2003000056 A PE2003000056 A PE 2003000056A PE 2003000056 A PE2003000056 A PE 2003000056A PE 20030925 A1 PE20030925 A1 PE 20030925A1
Authority
PE
Peru
Prior art keywords
phenyl
amino
substituted
hydroxamate
acid esters
Prior art date
Application number
PE2003000056A
Other languages
English (en)
Inventor
Stephen Douglas Barrett
Julie Ann Spicer
Gordon William Rewcastle
Michael David Kaufman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20030925A1 publication Critical patent/PE20030925A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A ESTERES HIDROXAMATO DE ACIDO N-(4-FENIL-SUSTITUIDO)-ANTRANILICO DE FORMULA I DONDE W ES EL GRUPO a, b, ENTRE OTROS; R2 ES H, METILO, F, Cl; R3 ES H, F; R4 ES -CH2S(CH2)m(CH3), -CF2CF(CF3)2, -C(CF3)3, ENTRE OTROS; m ES 0-1; n ES 0-2; p ES 1-5; q ES 1-2; R5 ES H , F, Br, Cl; R6 ES H, METILO, ETILO. SON COMPUESTOS PREFERIDOS 4-[[2,3-DIFLUORO-6-[[(2-HIDROXIETOXI)AMINO]CARBONIL]FENIL]AMINO]BENZOATO DE METILO, ACIDO 4-[[2,3-DIFLUORO-6-[[(2-HIDROXIETOXI)AMINO]CARBONIL]FENIL]AMINO]BENZOICO, 3,4-DIFLUORO-2-[[2-FLUORO-4-(3-METOXI-1-PROPINIL]FENIL]AMINO]BENZOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICON FARMACEUTICA PARA EL TRATAMIENTO DE RESTENOSIS, PSORIASIS, ATEROESCLEROSIS.
PE2003000056A 2002-01-23 2003-01-17 Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico PE20030925A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35110602P 2002-01-23 2002-01-23

Publications (1)

Publication Number Publication Date
PE20030925A1 true PE20030925A1 (es) 2003-10-29

Family

ID=27613459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000056A PE20030925A1 (es) 2002-01-23 2003-01-17 Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico

Country Status (14)

Country Link
US (1) US6770778B2 (es)
EP (1) EP1467965A1 (es)
JP (1) JP2005515251A (es)
AR (1) AR038212A1 (es)
BR (1) BR0307071A (es)
CA (1) CA2472367A1 (es)
DO (1) DOP2003000556A (es)
HN (1) HN2003000038A (es)
MX (1) MXPA04005528A (es)
PA (1) PA8563901A1 (es)
PE (1) PE20030925A1 (es)
TW (1) TW200302084A (es)
UY (1) UY27618A1 (es)
WO (1) WO2003062189A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2622755C (en) 2005-10-07 2017-01-31 Exelixis, Inc. Azetidines as mek inhibitors
EP2101759B1 (en) 2006-12-14 2018-10-10 Exelixis, Inc. Methods of using mek inhibitors
KR20100063109A (ko) * 2007-10-05 2010-06-10 사노피-아벤티스 도이칠란트 게엠베하 통증 치료에서 설포닐-치환된 2-설포닐아미노벤조산 ｎ-페닐아미드의 용도
EP2346818B1 (en) 2008-11-10 2012-12-05 Bayer Intellectual Property GmbH Substituted sulphonamido phenoxybenzamides
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2538943B1 (en) 2010-02-25 2016-03-30 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN104394855A (zh) 2012-05-31 2015-03-04 拜耳医药股份有限公司 用于测定肝细胞癌(hcc)患者的治疗的有效响应的生物标记
GEP201706690B (en) 2012-10-12 2017-06-26 Exelixis Inc Novel process for making compounds for use in treatment of cancer
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
CN103508965B (zh) * 2013-09-27 2015-04-08 天津大学 一种二苯西平类衍生物的合成方法
CN105646438A (zh) * 2015-12-22 2016-06-08 天津大学 一种缩酮类糖醇基小分子凝胶因子及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) * 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
NL62219C (es) * 1945-05-07
US2553914A (en) * 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
US3781358A (en) * 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
CH541608A (de) 1970-11-06 1973-09-15 Ciba Geigy Ag Verfahren zur Herstellung von Nitrodiphenylaminen und deren Verwendung
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
DE3608726A1 (de) 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5068250A (en) * 1988-09-29 1991-11-26 Trustees Of University Of Pennsylvania Irreversible ligands for nonsteroidal antiinflammatory drug and prostaglandin binding sites
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
AU6858996A (en) 1995-08-28 1997-03-19 Interlab Corporation Pharmaceutical compositions for the treatment of infectious diseases
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
AU5610398A (en) 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
CA2290509A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
AU9503998A (en) 1997-10-28 1999-05-17 Warner-Lambert Company Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents
WO2000040235A2 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
AU2483400A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 4'heteroaryl diarylamines
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯

Also Published As

Publication number Publication date
TW200302084A (en) 2003-08-01
UY27618A1 (es) 2003-08-29
JP2005515251A (ja) 2005-05-26
HN2003000038A (es) 2003-01-21
CA2472367A1 (en) 2003-07-31
WO2003062189A1 (en) 2003-07-31
MXPA04005528A (es) 2005-03-23
DOP2003000556A (es) 2003-10-31
BR0307071A (pt) 2004-12-28
AR038212A1 (es) 2005-01-05
PA8563901A1 (es) 2003-09-05
EP1467965A1 (en) 2004-10-20
US6770778B2 (en) 2004-08-03
US20030232889A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
PE20030925A1 (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
RU2361870C2 (ru) Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение
PE20040728A1 (es) Inhibidores de caspasa
PE20030856A1 (es) Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico
PE20000064A1 (es) Compuesto de tiourea y benzamida, composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20040898A1 (es) Nuevos compuestos derivados de pirimidina
AR032781A1 (es) Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
PE20030227A1 (es) Agonistas de ppar
PE20061124A1 (es) Compuestos y derivados de dibencil amina
EA200501462A1 (ru) Альфа-замещенные карбоновые кислоты в качестве модуляторов ppar
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
KR960703580A (ko) 눈의 염증성 질환을 치료하기 위한 3-벤조일페닐아세트산 유도체를 함유하는 국소투여가능한 조성물(Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders)
PE20021073A1 (es) Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3
PE20040666A1 (es) Derivados novedosos de piperidina
CN1353688A (zh) 由苯甲酸酯衍生的化合物、含有上述化合物的组合物及其用途
PE20040558A1 (es) Derivados de fluorobenzamidas como inhibidores selectivos de la monoamino oxidasa b
CO5670350A2 (es) Proceso para preparar derivados de acido 5-(1,3-oxazol- 2-il) benzoico
PE20010851A1 (es) Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
HUP0303584A2 (hu) Egy hidroximsav-halogenid-származék alkalmazása neurodegeneratív betegségek kezelésére
PE20040668A1 (es) Nuevos derivados de piperidina
PE20030929A1 (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
PE20081142A1 (es) Formulaciones semisolidas de inhibidores de enzima fosfolipasa
SE8700250D0 (sv) 8alfa-acylaminoergolines, their production and pharmaceutical compositions containing them
FI955238A0 (fi) Uudet 5-(aryylioksimetyyli)oksatsoliinit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset

Legal Events

Date Code Title Description
FC Refusal